The U.S. Food and Drug Adminstration Approves Pharmacyclics Product For Treatment of Disease
November 13, 2013 at 14:03 PM EST
On Wednesday, the U.S. Food and Drug Administration reported on its website that it has approved Imbruvica for the treatment of rare blood cancer. Imbruvica is co-marketed by Pharmacyclics (NASDAQ: PCYC ). According to the FDA, Imbruvica is intended for patients with mantle cell lymphoma (MCL), a rare and
